SI1835922T1 - Kombinacijsko zdravljenje multiple skleroze - Google Patents

Kombinacijsko zdravljenje multiple skleroze

Info

Publication number
SI1835922T1
SI1835922T1 SI200530731T SI200530731T SI1835922T1 SI 1835922 T1 SI1835922 T1 SI 1835922T1 SI 200530731 T SI200530731 T SI 200530731T SI 200530731 T SI200530731 T SI 200530731T SI 1835922 T1 SI1835922 T1 SI 1835922T1
Authority
SI
Slovenia
Prior art keywords
multiple sclerosis
combination treatment
cda
alpha
agent
Prior art date
Application number
SI200530731T
Other languages
English (en)
Inventor
Luca Giampiero De
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of SI1835922T1 publication Critical patent/SI1835922T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transplanting Machines (AREA)
SI200530731T 2004-12-22 2005-12-20 Kombinacijsko zdravljenje multiple skleroze SI1835922T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63867404P 2004-12-22 2004-12-22
EP04106910 2004-12-22
EP05823965A EP1835922B1 (en) 2004-12-22 2005-12-20 Combination treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
SI1835922T1 true SI1835922T1 (sl) 2009-10-31

Family

ID=35789196

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530731T SI1835922T1 (sl) 2004-12-22 2005-12-20 Kombinacijsko zdravljenje multiple skleroze

Country Status (17)

Country Link
US (1) US20100129353A1 (sl)
EP (1) EP1835922B1 (sl)
JP (1) JP2008524310A (sl)
AT (1) ATE431740T1 (sl)
AU (1) AU2005318183B2 (sl)
CA (1) CA2590471A1 (sl)
CY (1) CY1109316T1 (sl)
DE (1) DE602005014570D1 (sl)
DK (1) DK1835922T3 (sl)
ES (1) ES2325552T3 (sl)
HR (1) HRP20090417T1 (sl)
IL (1) IL183924A (sl)
NO (1) NO20073635L (sl)
PL (1) PL1835922T3 (sl)
PT (1) PT1835922E (sl)
SI (1) SI1835922T1 (sl)
WO (1) WO2006067134A1 (sl)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) * 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) * 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) * 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1696031E (pt) * 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5837242A (en) * 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
AU2003213231A1 (en) * 2002-02-25 2003-09-09 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
CN101912615B (zh) * 2003-03-28 2013-03-27 阿莱斯贸易有限公司 用于改善的经口和透粘膜输送的克拉屈滨制剂

Also Published As

Publication number Publication date
EP1835922B1 (en) 2009-05-20
JP2008524310A (ja) 2008-07-10
ATE431740T1 (de) 2009-06-15
HRP20090417T1 (en) 2009-09-30
AU2005318183B2 (en) 2011-03-31
AU2005318183A1 (en) 2006-06-29
IL183924A0 (en) 2007-10-31
WO2006067134A1 (en) 2006-06-29
EP1835922A1 (en) 2007-09-26
IL183924A (en) 2010-11-30
CA2590471A1 (en) 2006-06-29
PT1835922E (pt) 2009-07-08
NO20073635L (no) 2007-09-24
US20100129353A1 (en) 2010-05-27
PL1835922T3 (pl) 2009-10-30
DE602005014570D1 (sl) 2009-07-02
CY1109316T1 (el) 2014-07-02
DK1835922T3 (da) 2009-08-03
ES2325552T3 (es) 2009-09-08

Similar Documents

Publication Publication Date Title
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
GB2506085A (en) Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
NO20052362L (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof
WO2005009363A3 (en) Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
JP2003528919A5 (sl)
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
DE602005014570D1 (sl)
TW200628162A (en) Combination treatment for multiple sclerosis
MXPA04005207A (es) Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
WO2003103675A3 (en) COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
TH100271B (th) การบำบัดแบบมีการรวมสำหรับโรคปลอกประสาทเสื่อมแข็ง